BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 25151356)

  • 1. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.
    Gatza ML; Silva GO; Parker JS; Fan C; Perou CM
    Nat Genet; 2014 Oct; 46(10):1051-9. PubMed ID: 25151356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2.
    Rantala JK; Edgren H; Lehtinen L; Wolf M; Kleivi K; Vollan HK; Aaltola AR; Laasola P; Kilpinen S; Saviranta P; Iljin K; Kallioniemi O
    Neoplasia; 2010 Nov; 12(11):877-88. PubMed ID: 21082043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
    Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
    Klæstad E; Opdahl S; Engstrøm MJ; Ytterhus B; Wik E; Bofin AM; Valla M
    Breast Cancer Res Treat; 2020 Feb; 180(1):73-86. PubMed ID: 31950385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.
    Mehta GA; Parker JS; Silva GO; Hoadley KA; Perou CM; Gatza ML
    Breast Cancer Res Treat; 2017 Apr; 162(3):439-450. PubMed ID: 28176176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
    PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.
    Kobos R; Nagai M; Tsuda M; Merl MY; Saito T; Laé M; Mo Q; Olshen A; Lianoglou S; Leslie C; Ostrovnaya I; Antczak C; Djaballah H; Ladanyi M
    J Pathol; 2013 Apr; 229(5):743-754. PubMed ID: 23288701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ovarian cancer subtype-specific network modules and candidate drivers through an integrative genomics approach.
    Zhang D; Chen P; Zheng CH; Xia J
    Oncotarget; 2016 Jan; 7(4):4298-309. PubMed ID: 26735889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.
    Kristensen VN; Vaske CJ; Ursini-Siegel J; Van Loo P; Nordgard SH; Sachidanandam R; Sørlie T; Wärnberg F; Haakensen VD; Helland Å; Naume B; Perou CM; Haussler D; Troyanskaya OG; Børresen-Dale AL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2802-7. PubMed ID: 21908711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer.
    Yu H; Jiang Y; Liu L; Shan W; Chu X; Yang Z; Yang ZQ
    Oncotarget; 2017 Feb; 8(8):13099-13115. PubMed ID: 28055972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
    Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
    Elife; 2020 May; 9():. PubMed ID: 32401198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
    Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
    BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.
    Cornen S; Guille A; Adélaïde J; Addou-Klouche L; Finetti P; Saade MR; Manai M; Carbuccia N; Bekhouche I; Letessier A; Raynaud S; Charafe-Jauffret E; Jacquemier J; Spicuglia S; de The H; Viens P; Bertucci F; Birnbaum D; Chaffanet M
    PLoS One; 2014; 9(1):e81843. PubMed ID: 24416132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
    Montes de Oca R; Gurard-Levin ZA; Berger F; Rehman H; Martel E; Corpet A; de Koning L; Vassias I; Wilson LO; Meseure D; Reyal F; Savignoni A; Asselain B; Sastre-Garau X; Almouzni G
    Mol Oncol; 2015 Mar; 9(3):657-74. PubMed ID: 25497280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators.
    Simeone I; Ceccarelli M
    J Transl Med; 2023 Jan; 21(1):55. PubMed ID: 36717859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
    Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
    Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
    Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
    Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
    O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
    Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.